Latest Headlines

Latest Headlines

GSK obtains rights to inhaled nanoparticles made using Liquidia's PRINT platform

GlaxoSmithKline now has rights to develop inhaled therapeutics using Liquidia's PRINT particle engineering technology. The development builds on a drug delivery alliance between the two companies that commenced in 2012.

Glaxo's consumer health CEO lays out blueprint for margin turnaround

GlaxoSmithKline is pinning its hopes on consumer health, a unit whose margins it expects to see at 20% by 2020. But just how does it expect to get there?

Troubled GlaxoSmithKline to shutter R&D facility in France

Late last year GlaxoSmithKline set its sights on reorganizing and downsizing its R&D group, laying off hundreds of staffers in North Carolina as it concentrates research in the Philadelphia area and around Stevenage in the U.K. And now it's taking the ax to a satellite lab in France.

Intarcia nabs GSK castoff Phoundry, beefs up diabetes pipeline

Just weeks after a group of castaways from the big GlaxoSmithKline reorg in North Carolina started their own biotech, Phoundry, focusing on establishing a pipeline of new peptide therapies, they've found a buyer for the company. Boston-based Intarcia says it is acquiring Phoundry with an eye to beefing up its work related to the ultra-extended-release diabetes therapy ITCA 650.

GlaxoSmithKline's asthma injection heads for EU approval

GlaxoSmithKline got a positive opinion from European regulators on its new treatment for severe asthma, setting the stage for a likely approval later this year.

BMJ: New analysis shows increased suicide rates in teens taking GSK's Paxil

GlaxoSmithKline has faced its fair share of scrutiny over a study of its antidepressant Paxil in teenagers, with some experts claiming that the company wrote off harmful side effects linked to the med. Now, a re-analysis of the original study shows that the trial trumpeted Paxil's benefits while downplaying serious side effects including suicide.

GSK settles big media review, chooses incumbents for estimated $900M account

And the winner is … everyone. GlaxoSmithKline chose both of its incumbent agencies to continue handling media planning and buying for its newly consolidated GSK Consumer Healthcare business.

Controversial resveratrol triggers new headlines--this time for Alzheimer's

Georgetown's Dr. R. Scott Turner tested a therapeutic grade formulation of resveratrol in Alzheimer's patients, looking at two suspected biomarkers for the disease, the soluble proteins amyloid beta 42 and Abeta 40. Abeta 40 levels remained level among the group getting purified resveratrol, while the control group registered telltale declines as their dementia worsened.

Back-to-school MenB shots are de rigueur at some colleges, but others won't stock them

The Centers for Disease Control immunization committee stopped short of advising routine vaccination against meningitis B, instead leaving the decision up to doctors and families. And now, U.S. universities are tackling MenB vaccination in a multitude of ways.

With limited ACIP nod, U.S. universities take different approaches to Pfizer, GSK MenB jabs

The CDC's Advisory Committee on Immunization Practices has stopped short of recommending routine meningitis B immunization, leaving the decision to doctors and families whether young adults aged 16 to 23 should be vaccinated. Result? U.S. universities are taking varying approaches when it comes to MenB jabs and their students.